Trials / Recruiting
RecruitingNCT03689595
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30,000 (estimated)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Accepted
Summary
The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
Detailed description
The goal of the PROMISE research study is to determine clinical/genomic alterations present in individuals with MGUS and SMM, who are diagnosed through screening of a high-risk population. We also seek to determine clinical/genomic/epigenetic and immune environmental predictors of progression to multiple myeloma in patients with MGUS and SMM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Sample of Blood | Collection of blood sample from participants |
Timeline
- Start date
- 2018-10-31
- Primary completion
- 2033-10-31
- Completion
- 2033-10-31
- First posted
- 2018-09-28
- Last updated
- 2025-11-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03689595. Inclusion in this directory is not an endorsement.